Citadel Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Citadel Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-55,500	Closed	-$533K	–	16024
2024 Q4	$533K	Buy	55,500 +33,300	+150%	+$174K	﹤0.01%	8410
2024 Q3	$63.5K	Buy	22,200 +11,100	+100%	+$34.4K	﹤0.01%	11651
2024 Q2	$32.4K	Buy	11,100 +5,500	+98%	+$15K	﹤0.01%	12178
2024 Q1	$17.9K	Buy	+5,600	New	+$18.7K	﹤0.01%	13086
2023 Q4	–	Sell	-11,300	Closed	-$26.9K	–	15459
2023 Q3	$26.9K	Sell	11,300 -8,700	-44%	-$18.2K	﹤0.01%	12374
2023 Q2	$35.2K	Buy	20,000 +14,500	+264%	+$37K	﹤0.01%	12190
2023 Q1	$16.9K	Sell	5,500 -14,800	-73%	-$88.7K	﹤0.01%	13180
2022 Q4	$108K	Buy	+20,300	New	+$92.8K	﹤0.01%	11115

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's PSTX Position: Q1 2025 in Review

Citadel Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 154,764 shares — an estimated $1.49M sold.

Citadel Advisors first reported a position in PSTX in Q3 2020 and held it in 13 quarters. The position peaked at $1.49M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Citadel Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Citadel Advisors sold 154,764 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.49M.
Citadel Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 13 quarters.
Citadel Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $1.49M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.